Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 19, 2022
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe AsthmaIan D Pavord, Yamo Deniz, Jonathan Corren, et al.
Journal of Asthma and Allergy|August 25, 2021
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized TrialJonathan Corren, Sarbjit S Saini, Remi Gagnon, et al.
The New England Journal of Medicine|August 5, 2011
Lebrikizumab treatment in adults with asthmaJonathan Corren, Robert F Lemanske, Nicola A Hanania, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2023
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, et al.
ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Journal of Asthma and Allergy|December 28, 2020
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung FunctionIan D Pavord, Salman Siddiqui, Alberto Papi, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 19, 2022
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe AsthmaIan D Pavord, Yamo Deniz, Jonathan Corren, et al.
Journal of Asthma and Allergy|August 25, 2021
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized TrialJonathan Corren, Sarbjit S Saini, Remi Gagnon, et al.
The New England Journal of Medicine|August 5, 2011
Lebrikizumab treatment in adults with asthmaJonathan Corren, Robert F Lemanske, Nicola A Hanania, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 24, 2023
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)Ian D Pavord, Flavia C L Hoyte, Andrew W Lindsley, et al.
ERJ Open Research|February 4, 2020
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaMario Castro, Klaus F Rabe, Jonathan Corren, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Journal of Asthma and Allergy|December 28, 2020
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung FunctionIan D Pavord, Salman Siddiqui, Alberto Papi, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
Pageof 15